Project Details
Description
A Randomized Phase 3 Study of Tasisulam Administered as Intravenous Infusion on Day 1 of a 28-Day cycle vs. Paclitaxel as Second-Line Treatment in Patients with Metastatic Melanoma
| Status | Finished |
|---|---|
| Effective start/end date | 9/30/09 → 11/30/12 |
Funding
- ELI LILLY AND COMPANY
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.